CL2022002207A1 - Formulations of vaccine compositions against dengue virus (application divisional 202001463). - Google Patents

Formulations of vaccine compositions against dengue virus (application divisional 202001463).

Info

Publication number
CL2022002207A1
CL2022002207A1 CL2022002207A CL2022002207A CL2022002207A1 CL 2022002207 A1 CL2022002207 A1 CL 2022002207A1 CL 2022002207 A CL2022002207 A CL 2022002207A CL 2022002207 A CL2022002207 A CL 2022002207A CL 2022002207 A1 CL2022002207 A1 CL 2022002207A1
Authority
CL
Chile
Prior art keywords
dengue virus
formulations
vaccine compositions
compositions against
against dengue
Prior art date
Application number
CL2022002207A
Other languages
Spanish (es)
Inventor
S Ryan Michael
P Martin Sherrie-Ann
JONES Morrisa
Stanbro Justin
Bhambhani Akhilesh
Thomas Blue Jeffrey
Joanne PIXLEY Heidi
J Green-Trexler Erin
Ann Isopi Lynne
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Priority to CL2022002207A priority Critical patent/CL2022002207A1/en
Publication of CL2022002207A1 publication Critical patent/CL2022002207A1/en

Links

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere a formulaciones de vacuna contra el virus del dengue que comprenden al menos un virus del dengue vivo atenuado, un amortiguador, un azúcar, un derivado de celulosa, un glicol o alcohol de azúcar, opcionalmente un álcali o sal alcalina y un aminoácido.The present invention relates to dengue virus vaccine formulations comprising at least one live attenuated dengue virus, a buffer, a sugar, a cellulose derivative, a glycol or sugar alcohol, optionally an alkali or alkali salt, and an amino acid.

CL2022002207A 2022-08-12 2022-08-12 Formulations of vaccine compositions against dengue virus (application divisional 202001463). CL2022002207A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CL2022002207A CL2022002207A1 (en) 2022-08-12 2022-08-12 Formulations of vaccine compositions against dengue virus (application divisional 202001463).

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CL2022002207A CL2022002207A1 (en) 2022-08-12 2022-08-12 Formulations of vaccine compositions against dengue virus (application divisional 202001463).

Publications (1)

Publication Number Publication Date
CL2022002207A1 true CL2022002207A1 (en) 2023-03-03

Family

ID=85792726

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022002207A CL2022002207A1 (en) 2022-08-12 2022-08-12 Formulations of vaccine compositions against dengue virus (application divisional 202001463).

Country Status (1)

Country Link
CL (1) CL2022002207A1 (en)

Similar Documents

Publication Publication Date Title
CL2020001463A1 (en) Formulations of vaccine compositions against dengue virus.
NO20081889L (en) Solid vaccine formulation
CO2022011728A2 (en) Compositions and uses of glp-1
BR112019009133A2 (en) swine parvovirus vaccine
AR081809A1 (en) PHARMACEUTICAL COMPOSITIONS THAT INCLUDE A POLYPEPTIDE THAT INCLUDES AT LEAST A CXXC REASON AND HETEROLOGICAL ANTIGENS AND USES OF THE SAME
AR118881A1 (en) INACTIVATED VIRUS COMPOSITIONS AND ZIKA VACCINE FORMULATIONS
BR112022000117A2 (en) Compacted compositions of macitentana, methods and uses thereof.
CL2022002207A1 (en) Formulations of vaccine compositions against dengue virus (application divisional 202001463).
WO2022047054A3 (en) Inhibitors of sars cov-2 infection and uses thereof
CL2023002560A1 (en) Stable antibody formulation
JP7296316B2 (en) Lissamine green ophthalmic solution and its use in ophthalmology
PE20220486A1 (en) SOLID COMPOSITIONS COMPRISING AN EGF(A) DERIVATIVE AND A SALT OF N-(8-(2-HYDROXYBENZOYL)AMINO)CAPRYLIC ACID
JP5582768B2 (en) Nonionic silicone hydrogel contact lens ophthalmic composition
AR117707A1 (en) PROTEIN SOLUTION FORMULATION CONTAINING A HIGH CONCENTRATION OF AN ANTI-VEGF ANTIBODY
ECSP11011179A (en) A COMPOSITION OF BOTANICAL REPELLENT BASED ON ALLIUM SAVITUM AND HUMIC ACIDS TO COMBAT PEST INSECTS AND PROCEDURE OF OBTAINING AND USES.
CL2022002292A1 (en) Sodium acetate and pharmaceutical compositions thereof
BR112023022114A2 (en) PHARMACEUTICAL COMPOUND COMPRISING GPR40 AGONIST AND SGLT-2 INHIBITOR
PE20231946A1 (en) SOLID FORMULATION
BR112023005001A2 (en) INFECTIOUS BRONCHITIS STRAIN DMV1639 VIRUS ISOLATE
US11529312B2 (en) Francisella lipids as broad anti-inflammatory therapeutics and associated methods of use
AR121363A1 (en) COMPOSITIONS AND USES OF GLP-1
AR062674A1 (en) WATERY FORMULATION UNDERSTANDING AN ANTITUMORAL AGENT
AR119039A1 (en) AN IMMUNOGENIC FORMULATION THAT INDUCES PROTECTION AGAINST ESCHERICHIA COLI PRODUCING SHIGA TOXIN (ECTS)
Hook et al. Real-Time Optical Imaging of MRSA-Induced Alveolar Injury Mechanisms
AR120774A1 (en) COMPOSITIONS OF BILE ACIDS AND PHENYLBUTYRATE COMPOUNDS